KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

Xu, Rui; Ji, Sun; Zhang, Shi Rong; Zhu, Guan Shan; Li, Li Bo; Liao, Yu Lin; Xie, Jian; Liao, Wang Jun

doi:10.1016/j.biopha.2010.06.009

Cited by 55 publications

(54 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some investigators have also identified subsets of both extrahepatic cholangiocarcinoma and ICC that appear to be driven by BRAF mutations [47][48][49]. However, this study did not find any BRAF mutations in the series of 28 ICCs, a findingalso reported byothers [50]. TP53 alterations have been reported in 39% (232 of 596) of biliary tract cancers and specifically in 41% (106 of 259) of bile duct carcinomas (as shown in the COSMIC database in June 2012).…”

Section: Discussionmentioning

confidence: 52%

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

Wang²,

et al. 2014

View full text Add to dashboard Cite

Background. Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that is rarely curable by surgery and is rapidly increasing in incidence. Relapsed ICC has a poor prognosis, and current systemic nontargeted therapies are commonly extrapolated from those used in other gastrointestinal malignancies. We hypothesized that genomic profiling of clinical ICC samples would identify genomic alterations that are linked to targeted therapies and that could facilitate a personalized approach to therapy. Methods. DNA sequencing of hybridization-captured libraries was performed for 3,320 exons of 182 cancer-related genes and 36 introns of 14 genes frequently rearranged in cancer. Sample DNA was isolated from 40 mm of 28 formalin-fixed paraffin-embedded ICC specimens and sequenced to high coverage.

show abstract

Section: Discussionmentioning

confidence: 52%

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

Wang²,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, mutual mutations in these 3 genes in different types of cancer have not been thoroughly investigated. Xu et al (2011) found that only 5.9% of mutations were in both PIK3CA and KRAS in human cancer of cholangiocarcinoma. In our study, we found that PIK3CA mutations coexisted with KRAS mutations in one sample.…”

Section: Resultsmentioning

confidence: 99%

Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai

Wang¹,

Dai²,

Li³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Phosphatidylinositol-3-OH kinase and RAS-activated signaling pathways play an important role in tumor formation. Abnormalities in relevant genes play essential roles in the occurrence and development of many human cancers. Studies of breast cancer have mainly focused on the women in western countries, but few studies have examined the frequency of mutations in PIK3CA, BRAF, and KRAS in Chinese breast cancer patients. In this study, we conducted sequence analysis of PIK3CA, BRAF, and KRAS and determined relationships with the occurrence of breast cancer in women from Qinghai. DNA was extracted from 25 cases of human breast cancer tissue samples. PIK3CA, BRAF, and KRAS mutation analysis was performed by polymerase chain reaction and DNA sequencing. No mutations were found in PIK3CA, BRAF, and KRAS of adjacent tissues. However, PIK3CA mutations were observed in 32% (8) of the 25 breast cancer tissues examined, in which exon 9 accounted for 4% (1), exon 20 accounted for 28% (7), and no mutations were found in exon 1 of PIK3CA. Sequencing of exon 2 of KRAS suggested that 20% (5) of the 25 samples harbored a mutation and 16% (4) 14840-14846 (2015) harbored a mutation. Any mutation in these 3 oncogenes may induce the occurrence and development of breast cancer.

show abstract

“…[100][101][102][103] An Italian study showed that 23% (15/65) of hepatocellular carcinomas harboured the BRAF V600E mutation, whereas many other earlier studies had failed to detect any BRAF mutation. 100 In another study in Germany, BRAF mutation was noted in 22% (15/69) of cholangiocarcinomas.…”

Section: Braf and Hepatobiliary Carcinomasmentioning

confidence: 99%

“…101 On the other hand, the other available studies did not find any BRAF mutation in this cancer. 102 Carcinoma of gall bladder is uncommon. Nevertheless, BRAF mutation has been noted in 33% (7/21) of the cancer in one study.…”

Section: Braf and Hepatobiliary Carcinomasmentioning

confidence: 99%

Clinicopathological relevance of BRAF mutations in human cancer

et al. 2013

View full text Add to dashboard Cite

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

Cited by 55 publications

References 30 publications

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai

Clinicopathological relevance of BRAF mutations in human cancer

Contact Info

Product

Resources

About